Peptides and the law in the European Union – legal status of research reagents

The most frequently repeated narrative about peptides goes something like this: “peptides are in a gray area”, “it’s not entirely legal, but not illegal either”, “the research reagents market operates in the legal gap between drugs and supplements”. Each of these statements is inaccurate at best and downright false at worst. Research peptides in the European Union have a clearly defined legal status. It is different from the status of drugs, dietary supplements and cosmetics, but that does not make it “gray” – it just makes it another regulatory category.

Understanding this status is important for three reasons. Firstly, for research teams planning to work with peptide reagents – to work in accordance with EU law. Secondly, for individual buyers – to distinguish legal activities from legally risky ones. Thirdly, for the supplier himself – not to buy from entities operating at the border of the law.

This article brings together the current legal status of research peptides in the European Union in one place. We focus on the status of peptides as laboratory reagents (Research Use Only) – because this is the dominant category in the turnover of research peptides in the EU.

📖 The following article is educational and describes the current legal status of research peptides in the European Union. The text does not constitute legal advice on specific matters. For specific questions regarding individual legal situations, please consult a lawyer specializing in pharmaceutical and chemical law.

Three regulatory pathways – where the peptide fits in

Peptide as a chemical molecule can enter into three distinct regulatory categories in the European Union. These categories are mutually exclusive – one particular preparation with a particular peptide belongs to one of them, not to a “gap” between them.

Category one – medicinal product (drug)

A peptide registered as a medicinal product is subject to:

• EU pharmaceutical law — Regulation 726/2004 (central procedure run by EMA) or Directive 2001/83/EC (national procedures and mutual recognition between Member States)
• Prescription sales or in non-pharmacy trade (depending on the category)
• GMP requirements (Good Manufacturing Practice) for production
• Full registration documentation the European Medicines Agency or national competent authority
• Pharmacovigilance — mandatory monitoring of side effects

Examples of peptides registered as medicines in the EU:

• Insulin and its analogues
• Semaglutide (Ozempic, Wegovy, Rybelsus)
• Liraglutide (Saxenda, Victoza)
• Tirzepatide (Mounjaro, Zepbound)
• Oxytocin (Syntocinon – for obstetric indications)
• Octreotide (Sandostatin)

For this category, sale requires a medical prescription (or OTC indications for selected items), and use is under medical supervision.

Category two – cosmetic ingredient

The peptide can be registered as a cosmetic ingredient in accordance with Regulation 1223/2009/EC about cosmetic products.

Requirements:

• Topical application (cream, serum, mask)
• No medical claims (“heals”, “regenerates” in the medical sense – not cosmetic)
• Notification in Cosmetic Products Notification Portal (CPNP) — the EU central system
• Safety documentation (Cosmetic Product Safety Report – CPSR)
• Compliance with the list of permitted and prohibited substances in the annexes to the regulation

Example: GHK-Cu in anti-aging cosmetic preparations.

Category three – laboratory reagent (RUO)

This is the category that most peptides traded from research peptide suppliers fall into:

• Estado: chemical substance for scientific and laboratory research
• No registration as a medicine or dietary supplement
• Mandatory label: “For Research Use Only. Not for human use”
• Subject to REACH registration (Regulation 1907/2006/EC) in the EU if sales exceed 1 tonne per year (most research peptides do not reach this scale)
• Subject to general regulations on chemical substances — registration in European Chemicals Agency (ECHA) to the appropriate extent

Examples of RUO peptides in European circulation:

• BPC-157
• TB-500 (Thymosin Beta-4)
• Epithalon
• Semax, Selank
• DSIP
• Most anti-aging and regenerative peptides

What does the RUO status mean in practice?

Peptide as a laboratory reagent (Research Use Only):

May be

• Sold legally as a chemical reagent for laboratory tests in EU trade
• Imported and exported in B2B and B2C trade in accordance with the regulations on chemical substances and customs procedures
• Used in scientific research — both academic and in private laboratories
• Used in in vitro models (cell cultures) and in vivo (animal models compatible with Directive 2010/63/EU on the protection of animals used for scientific purposes)

CANNOT be

• Advertised as a medicine – this is a violation of EU pharmaceutical law (Directive 2001/83/EC, Article 86 – prohibition of advertising medicinal products to the general public for products not approved for non-pharmacy trade)
• Advertised as a dietary supplement — RUO peptide is not a dietary supplement in the European legal sense (Directive 2002/46/EC)
• Labeled as “for human consumption” — RUO label requirement: “For research use only. Not for human use”
• Sold with health claims (“cures”, “cures”, “effective in therapy”) – these are categories reserved for medicines, and in the scope of selected claims for dietary supplements under the control of Regulation 1924/2006/EC

What RUO peptide is NOT

RUO peptides should be clearly separated from four other categories:

• They are not dietary supplements — Regulation 178/2002/EC and Directive 2002/46/EC define a dietary supplement as a product for human consumption. RUO peptide is not “for consumption”
• They are not medicines — no registration of EMA in the central procedure or registration with the national competent authorities of the Member States in national or mutual recognition procedures
• They are not cosmetics — unless a specific peptide has a separate cosmetic registration with notification in CPNP (e.g. GHK-Cu as an ingredient of creams)
• They are not controlled substances — research peptides discussed in the One Peptides knowledge base are not included in the lists of the UN Convention on Psychotropic Substances or in the European registers of psychoactive substances maintained by European Monitoring Center for Drugs and Drug Addiction (EMCDDA)

Status of SARMs – Semi-separate category

SARMs (Selective Androgen Receptor Modulators) – Ostarine, Ligandrol, Cardarin, MK-677 and others – have partially separate regulatory status.

In terms of chemical trade in the EU

SARMs are classified as laboratory reagents (RUO) — analogously to research peptides. No registration as medicines, no registration as dietary supplements. Sale as laboratory testing chemicals is legal in the European Union. European Food Safety Authority (EFSA) and the national competent authorities have not accepted SARMs as ingredients of dietary supplements; any attempt to label SARMs as a supplement is a violation of food safety regulations.

Sports status

SARMs are found on WADA Prohibited Substances List (World Anti-Doping Agency) in the category S1.2 – other anabolic agents. Athletes subject to anti-doping control they cannot use SARMs at any time of the year – regardless of age, discipline or level of competition.

Status in other jurisdictions

Some jurisdictions outside the EU have introduced additional restrictions on SARMs:

• USA — in 2014, the Designer Anabolic Steroid Control Act was introduced, which partially limits the sale of selected steroid analogues. SARMs in the US are marketed as research reagents, but sales as a “sports supplement” are banned
• Australia, New Zealand, Canada — varying degrees of national restrictions
• European Union — without specific restrictions apart from the general chemical regulations and the RUO labeling requirement

Regulatory oversight bodies in the EU – who monitors what

The three regulatory categories are governed by three distinct regulatory regimes.

European Medicines Agency (EMA)

EMA manages the central registration procedure for medicinal products in the EU. For peptides registered as drugs (semaglutide, liraglutide, tirzepatide, octreotide), EMA maintains full registration documentation, monitors side effects (pharmacovigilance) and issues updates to registration indications. For the RUO peptide EMA is not a supervisory authority — RUO peptide is not a medicinal product and is not subject to EMA procedures.

European Food Safety Authority (EFSA)

EFSA assesses the safety of food ingredients and dietary supplements. For peptides considered as ingredients of dietary supplements (rare, but such cases do exist – e.g. some bioactive peptides from protein hydrolysates), EFSA issues opinions regarding marketing authorization. EFSA also maintains Health Claims procedures (Regulation 1924/2006/EC) – a list of permitted health claims for supplements. For the RUO peptide EFSA is not a supervisory authority — RUO peptide is not a dietary supplement.

European Chemicals Agency (ECHA)

ECHA registers chemical substances under REACH (Regulation 1907/2006/EC). Substances produced or imported into the EU in quantities exceeding 1 tonne per year require registration in ECHA with safety documentation (SDS – Safety Data Sheet, CSR – Chemical Safety Report). Most research peptides on the market do not meet this threshold and remain within the scope of the General Chemicals Regulations. ECHA also maintains lists of candidates for further regulation (substances of very high concern – SVHC).

National competent authorities

Each EU member state has its own system of authorities competent for drug registration, supervision of dietary supplements and customs control. EMA, EFSA and ECHA decisions are transposed into national law, but day-to-day enforcement (supplier inspections, customs decisions, infringement proceedings) is carried out at national level by these authorities.

RUO limit and user responsibility

The legal status of the RUO peptide defines, how the peptide can be sold. However, it does not define how it is actually used by the final buyer. This is an important distinction.

What is covered by the supplier’s responsibility

• Meeting the formal requirements of the RUO (labelling, COA, ban on therapeutic claims)
• Physicochemical quality of the peptide (compliance with the declared specification)
• Production and transport standards (cold chain, batch traceability)
• Company documentation (registration number, operator details, contact details)

Which is the buyer’s responsibility

• How to use the peptide after purchase
• Compliance with local research ethics regulations (if research is carried out – in the EU, Directive 2010/63/EU for animal testing)
• Compliance with professional rules (e.g. for athletes – WADA anti-doping control)
• Decisions regarding your own experiments

In particular:

• Peptide purchased as RUO and used in accordance with the declaration (laboratory tests, in vitro experiments, animal models in accordance with local regulations) – legally clean situation
• A peptide purchased as RUO and used in a manner contrary to the intended use of the product (e.g. human consumption) exceeds the scope of the supplier’s offer. Responsibility for such use rests solely with the person who did so

Why the “gray zone” is a myth

The narrative about the “grey area” of peptides comes from three sources.

Confusing regulatory categories

Research peptides are “neither drugs nor supplements” – because they are third category: laboratory reagents. It’s not a lack of categories – it’s a different category. Each of the three paths (medicine / cosmetic / RUO) has its own set of regulations, its own supervisory authorities and its own formal requirements.

Sellers operating illegally

Some peptide suppliers are indeed operating in an area of ​​legal ambiguity – selling peptides with therapeutic claims, labeling them as “supplements”, bypassing the COA requirement. Their practices are illegal, but that does not make the RUO peptide category itself a “gray area.” This makes the activities of specific suppliers illegal. For a practical guide to supplier verification, see the article what to pay attention to when buying research peptides.

Media disinformation

Popular science media often simplify regulatory topics by describing complex categories as “gray areas” or “loopholes.” For a research team planning to work with reagents, it is helpful to look at the law directly (EU Directives and Regulations available in EUR-Lex), not through the filter of simplifications.

Practical recommendations for various user groups

For academic research teams

Purchasing RUO peptides from professional suppliers is standard practice in European laboratories. Requirements:

• Full COA for each batch (needed for publication and internal audit)
• Invoice and origin documentation (accounting and customs compliance)
• Compliance with research ethics protocol (Directive 2010/63/EU if animal testing is carried out)
• Good Laboratory Practice (GLP) procedures where national jurisdiction or internal institute procedure requires it

For private and independent researchers

RUO status is available – peptides can be purchased as research reagents by private entities. You should:

• Choose suppliers with full company details, COA and a transparent QA procedure – a compendium of standards in research peptide quality guide
• Avoid suppliers operating in questionable communication channels (no operator data, sale only for cryptocurrencies without invoice)
• Be aware that the RUO status does not cover human use

For athletes

Athletes subject to doping control should check the current status on the WADA website:

• BPC-157 — Prohibited List, section S0 (non-approved substances)
• TB-500 / Thymosin Beta-4 — prohibited list, category S2 (peptide hormones and growth factors)
• SARMs (all) – prohibited list, category S1.2 (other anabolic agents)
• GLP-1 and incretin analogues — approved medicines (e.g. semaglutide, tirzepatide) are not on the 2026 List; analogues without approval for human therapeutic use fall under section S0

Violation may result in disqualification.

For people outside these groups

The RUO status of peptides includes sale as research reagents. People purchasing peptides without a specific research purpose should be aware of the RUO status does not contain a declaration of safety for use in humans nor guarantee of therapeutic quality. Any use of the peptide outside the research context is an individual decision with risk attributable to the purchaser.

⚠️ This article does not constitute legal advice for specific individual situations. For specific questions regarding the trade in peptides, running a research laboratory, import or export, consult a lawyer specializing in pharmaceutical, chemical or food law relevant to your jurisdiction.

Frequently asked questions

Related content in the knowledge base

• HPLC vs MS – methods for analyzing the purity of research peptides
• How to Dissolve Peptides – Step by Step Guide
• Peptide storage – temperature, light, stability
• analytical standards overview
• Bridge to another cluster: cosmetic regulatory frameworks (Regulation 1223/2009/EC CPNP)

Full documentation of One Peptides catalog peptides – with per-batch COA, RUO labeling and operator registration details – available at quality tests and certificates.

Bibliography

1. European Parliament and Council (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use
2. European Parliament and Council (2002). Directive 2002/46/EC on the approximation of the laws of the Member States relating to food supplements
3. European Parliament and Council (2009). Regulation (EC) No 1223/2009 on cosmetic products
4. European Parliament and Council (2006). Regulation (EC) No 1907/2006 – REACH
5. European Parliament and Council (2010). Directive 2010/63/EU on the protection of animals used for scientific purposes
6. European Parliament and Council (2006). Regulation (EC) No 1924/2006 on nutrition and health claims made on foods
7. European Parliament and Council (2004). Regulation (EC) No 726/2004 — Community procedures for the authorization and supervision of medicinal products and establishing a European Medicines Agency
8. World Anti-Doping Agency (2024). The 2024 prohibited list — international standard
9. European Medicines Agency (2014). Guideline on development, production, characterization and specification for recombinant proteins and peptides
10. European Chemicals Agency (2024). ECHA – substance registration under REACH

 

ℹ️ Disclaimer

All One Peptides products in the category of freeze-dried peptides and SARMs in capsules are reagents intended exclusively for laboratory and scientific research (Research Use Only). They are not medicines, dietary supplements or products intended for human consumption. The information in this article is educational in nature and describes the current legal status of research peptides in the European Union; they do not constitute legal advice for specific individual situations. For specific questions, please consult a lawyer specializing in pharmaceutical, chemical or food law relevant to your jurisdiction.